Belite Bio, Inc
NASDAQ · us_market
No AI summary generated yet for this ticker.
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
2026-05-27. The following slide deck was published by Belite Bio, Inc in conjunction with this event.
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and lowers the price target from $223 to $215.
2026-05-22. The following slide deck was published by Belite Bio, Inc in conjunction with their 2026 Q1 earnings call.
HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $200 price target.
Belite Bio Inc (BLTE) reports significant progress in clinical trials and commercial preparations, despite increased R&D and SG&A expenses.
Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch. On the company’s first-quarter 2026 earnings call, Chairman and
Have received our Phase 3 clinical study report in Q1 without delay in April we initiated our NDA rolling submission to the FDA for Stargardt disease. As well as engaging with the retinal community to raise awareness of Stargardt disease. In line with that commitment to bring Tinlarebant to patients around the world, This past quarter, we also announced that we have completed enrollment in our Phase 2/3 Dragon 2 clinical trial evaluating Tinlarebant for Stargardt disease.
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call May 20, 2026 4:30 PM EDTCompany ParticipantsJulie FallonYu-Hsin Lin - Chairman of the Board of Directors &...
Belite Bio, Inc. (NASDAQ:BLTE) reported first-quarter results on Wednesday that came in ahead of analyst forecasts, with the clinical-stage biotech group posting an adjusted loss per share of -$0.
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is unchanged from the same period last year.
Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet
Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
SAN DIEGO, May 15, 2026 -- Belite Bio, Inc. , , a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
Belite Bio, Inc (BLTE) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:40 PM EDTCompany ParticipantsYu-Hsin Lin - Chairman of the Board of...
Presenter SpeechTazeen Ahmad Good afternoon. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I am one of the senior biotech analysts here at the bank. It's my pleasure
SAN DIEGO, May 13, 2026 -- Belite Bio, Inc. , , a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have...
2026-05-06. The following slide deck was published by Belite Bio, Inc in conjunction with this event.
Belite Bio (BLTE) has moved into a new regulatory phase, initiating a rolling New Drug Application with the FDA for tinlarebant in Stargardt disease type 1. This step is supported by Phase 3 DRAGON trial data and multiple expedited designations. See our latest analysis for Belite Bio. Despite the regulatory momentum around tinlarebant, Belite Bio’s share price return has been weaker in the near term, with a 30 day share price return of 8.83% and a 90 day share price return of 10.65%. At the...
Belite Bio (NASDAQ:BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio begun a rolling submission of an NDA to the FDA for tinlarebant, a potential first-ever treatment for Stargardt disease type 1/STGD1. This rare, progressive genetic disorder leads to legal blindness and currently has no […]
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 52.0K | $8.29M | 0.01% | New | 2026-03-31 |
| StateStreet | passive | 16.0K | $2.56M | 0.00% | Added+2.0% | 2026-03-31 |
| TRowePrice | fundamental | 281.8K | $44.93K | 0.01% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.77 | — | — |
| 2026-05-20 | -0.64 | -0.68 | -5.78% |
| 2026-03-02 | -0.54 | -0.70 | -30.32% |
| 2025-11-10 | -0.49 | -0.65 | -32.65% |
| 2025-08-11 | -0.42 | -0.50 | -19.76% |
| 2025-05-14 | -0.36 | -0.45 | -23.29% |
| 2025-03-17 | -0.31 | -0.32 | -4.07% |
| 2024-11-12 | -0.30 | -0.28 | +6.67% |
| 2024-08-09 | -0.26 | -0.31 | -19.23% |
| 2024-05-14 | -0.28 | -0.27 | +5.26% |
| 2024-03-12 | -0.30 | -0.24 | +19.33% |
| 2023-11-14 | -0.32 | -0.40 | -25.00% |
| 2023-08-09 | -0.30 | -0.26 | +12.61% |
| 2023-05-10 | -0.23 | -0.33 | -43.48% |
| 2023-03-31 | -0.33 | -0.25 | +24.24% |
| 2022-11-03 | -0.24 | -0.24 | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BLTE | -6.89% | -14.12% | -9.86% | +122.26% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.86% | -9.48% | -6.42% | +109.57% |